Pravin  Dugel net worth and biography

Pravin Dugel Biography and Net Worth

EVP of IVERIC bio
Pravin U. Dugel, MD, is President. Dr. Dugel was previously Managing Partner, Retinal Consultants of Arizona and the Retinal Research Institute; Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California; and Founding Member, Spectra Eye Institute in Sun City, Arizona. Dr. Dugel has authored more than 200 papers, 35 book chapters, and has been invited to lecture at several marquis medical meetings and to serve as a visiting professor at universities worldwide, including in Japan, India, China, Malaysia, Egypt, the United Kingdom, France, Germany, Austria, Italy, Poland, Denmark, Norway, Czechoslovakia, Canada, and Australia. He is on the editorial board of several major medical journals. Dr. Dugel is internationally recognized as a major clinical researcher and has been a principal investigator in over 100 multicenter clinical trials. His research and educational contributions earned him the prestigious Senior Honor Award from the American Academy of Ophthalmology (AAO). He has been elected and previously served as the Retina Subspecialty Day Board Chairman for the American Academy of Ophthalmology Annual Meeting, as a member of the board of directors of the largest retina society in the United States, the American Society of Retina Specialists (ASRS), and the largest retina society in Europe, EURETINA.

Dr. Dugel is a member of the board of directors and current Chair of Orbis International’s Medical Advisory Board/Medical Strategic Committee. Orbis International is a non-profit organization focused on ophthalmology training and education in the developing world. With Orbis, Dr. Dugel travels to developing countries to teach surgical techniques to local ophthalmologists and provide free surgery for those suffering from preventable blindness.

Dr. Dugel graduated summa cum laude from Columbia University in New York City. He then attended UCLA School of Medicine. He completed his residency in ophthalmology at the USC Eye Institute, Keck School of Medicine. Thereafter, he completed his medical retina fellowship at the Bascom Palmer Eye Institute and his surgical retina fellowship at the USC Eye Institute, where he was elected to serve on the faculty as the Resident Director.

What is Pravin Dugel's net worth?

The estimated net worth of Pravin Dugel is at least $2.00 million as of April 5th, 2021. Dr. Dugel owns 50,000 shares of IVERIC bio stock worth more than $1,997,500 as of April 24th. This net worth estimate does not reflect any other investments that Dr. Dugel may own. Additionally, Dr. Dugel receives an annual salary of $984,820.00 as EVP at IVERIC bio. Learn More about Pravin Dugel's net worth.

How old is Pravin Dugel?

Dr. Dugel is currently 59 years old. There are 5 older executives and no younger executives at IVERIC bio. The oldest executive at IVERIC bio is Mr. Glenn P. Sblendorio M.B.A., CEO & Director, who is 67 years old. Learn More on Pravin Dugel's age.

What is Pravin Dugel's salary?

As the EVP of IVERIC bio, Inc., Dr. Dugel earns $984,820.00 per year. The highest earning executive at IVERIC bio is Mr. Glenn P. Sblendorio M.B.A., CEO & Director, who commands a salary of $1,360,000.00 per year. Learn More on Pravin Dugel's salary.

How do I contact Pravin Dugel?

The corporate mailing address for Dr. Dugel and other IVERIC bio executives is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. IVERIC bio can also be reached via phone at (609) 474-6755 and via email at [email protected]. Learn More on Pravin Dugel's contact information.

Has Pravin Dugel been buying or selling shares of IVERIC bio?

Pravin Dugel has not been actively trading shares of IVERIC bio over the course of the past ninety days. Most recently, Pravin Dugel sold 28,301 shares of the business's stock in a transaction on Monday, April 5th. The shares were sold at an average price of $6.34, for a transaction totalling $179,428.34. Following the completion of the sale, the executive vice president now directly owns 50,000 shares of the company's stock, valued at $317,000. Learn More on Pravin Dugel's trading history.

Who are IVERIC bio's active insiders?

IVERIC bio's insider roster includes David Carroll (CFO), Pravin Dugel (EVP), Anthony Gibney (EVP), Calvin Roberts (Director), Glenn Sblendorio (CEO), Christopher Simms (SVP), and Keith Westby (COO). Learn More on IVERIC bio's active insiders.

Are insiders buying or selling shares of IVERIC bio?

During the last year, insiders at the sold shares 6 times. They sold a total of 190,453 shares worth more than $6,660,860.65. The most recent insider tranaction occured on July, 3rd when COO Keith Westby sold 20,000 shares worth more than $789,000.00. Insiders at IVERIC bio own 2.7% of the company. Learn More about insider trades at IVERIC bio.

Information on this page was last updated on 7/3/2023.

Pravin Dugel Insider Trading History at IVERIC bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/5/2021Sell28,301$6.34$179,428.3450,000View SEC Filing Icon  
See Full Table

Pravin Dugel Buying and Selling Activity at IVERIC bio

This chart shows Pravin Dugel's buying and selling at IVERIC bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

IVERIC bio Company Overview

IVERIC bio logo
IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.
Read More

Today's Range

Now: $39.95
Low: $39.95
High: $39.95

50 Day Range

MA: $38.88
Low: $36.90
High: $39.95

2 Week Range

Now: $39.95
Low: $9.39
High: $39.99

Volume

N/A

Average Volume

3,616,141 shs

Market Capitalization

$5.50 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06